BRPI0509888A - miméticos de direção inversa e método relacionado aos mesmos - Google Patents

miméticos de direção inversa e método relacionado aos mesmos

Info

Publication number
BRPI0509888A
BRPI0509888A BRPI0509888-2A BRPI0509888A BRPI0509888A BR PI0509888 A BRPI0509888 A BR PI0509888A BR PI0509888 A BRPI0509888 A BR PI0509888A BR PI0509888 A BRPI0509888 A BR PI0509888A
Authority
BR
Brazil
Prior art keywords
reverse direction
disease
mimetics
biologically active
disclosed
Prior art date
Application number
BRPI0509888-2A
Other languages
English (en)
Inventor
Sung Hwan Moon
Jae Uk Chung
Sung Chan Lee
Masakatsu Eguchi
Michael Kahn
Kwang Won Jeong
Cu Nguyen
Soo Jin Lee
Original Assignee
Choongwae Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongwae Pharma Corp filed Critical Choongwae Pharma Corp
Publication of BRPI0509888A publication Critical patent/BRPI0509888A/pt
Publication of BRPI0509888B1 publication Critical patent/BRPI0509888B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

MIMéTICOS DE DIREçãO INVERSA E MéTODO RELACIONADO AOS MESMOS. São divulgados compostos comprimidos de maneira conformacional que copiam a estrutura secundária de regiões de direção inversa de peptídeos e proteínas biologicamente ativos. Tais estruturas miméticas de direção inversa têm utilidade sobre uma ampla faixa de campos, incluindo o uso como agentes diagnósticos e terapêuticos. São também divulgadas bibliotecas contendo as estruturas miméticas de direção inversa desta invenção, assim como métodos para a triagem das mesmas para identificar membros biologicamente ativos. A invenção também se relaciona ao uso de tais compostos para inibir ou tratar distúrbios modulados pela via de sinalização de Wnt, tais como o câncer, especialmente o câncer colorretal, a reestenose associada com a angioplastia, a doença do rim policístico, a doença da angiogênese anormal, a doença de artrite reumatóide, o complexo de esclerose tuberosa, a doença de Alzheimer, o crescimento ou a perda em excesso de cabelo, ou a colite ulcerativa.
BRPI0509888-2A 2004-04-16 2005-04-15 Compostos miméticos de direção inversa, composição farmacêutica e usos terapêuticos dos mesmos BRPI0509888B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/826,972 2004-04-16
US10/826,972 US7576084B2 (en) 2001-10-12 2004-04-16 Reverse-turn mimetics and method relating thereto
PCT/US2005/012799 WO2005116032A2 (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto

Publications (2)

Publication Number Publication Date
BRPI0509888A true BRPI0509888A (pt) 2007-10-16
BRPI0509888B1 BRPI0509888B1 (pt) 2021-10-13

Family

ID=35207478

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509888-2A BRPI0509888B1 (pt) 2004-04-16 2005-04-15 Compostos miméticos de direção inversa, composição farmacêutica e usos terapêuticos dos mesmos

Country Status (12)

Country Link
US (4) US7576084B2 (pt)
EP (1) EP1740588A2 (pt)
JP (1) JP5021459B2 (pt)
KR (1) KR101257824B1 (pt)
CN (1) CN1942472B (pt)
AU (1) AU2005247859B2 (pt)
BR (1) BRPI0509888B1 (pt)
CA (1) CA2562693C (pt)
MX (1) MXPA06011983A (pt)
NZ (1) NZ550691A (pt)
RU (1) RU2434017C2 (pt)
WO (1) WO2005116032A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20070129353A1 (en) * 2005-11-08 2007-06-07 Michael Kahn Alpha-helix mimetics and method relating to the treatment of cancer stem cells
US8394842B2 (en) 2006-03-28 2013-03-12 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
KR20090026302A (ko) * 2006-05-30 2009-03-12 주식회사 중외제약 줄기세포 분화의 유도 또는 억제를 위한 조성물
MX2010013277A (es) * 2008-06-06 2011-04-27 Prism Biolab Corp Mimeticos de helice alfa y metodos relacionados con los mismos.
JP5545573B2 (ja) * 2008-10-14 2014-07-09 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ アルファへリックスミメティック及び関連の方法
CA2758904C (en) * 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
EP2427451B1 (en) 2009-05-07 2019-03-20 PRISM BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
US20120296067A1 (en) 2010-02-03 2012-11-22 Prism BioLab Co., Ltd. Compound capable of binding to naturally occurring denatured protein, and method for screening for the compound
KR102168006B1 (ko) 2010-10-07 2020-10-20 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
CN103209982B (zh) * 2010-10-14 2016-03-16 Jw制药公司 反转模拟物的化合物、其制造方法及其用途
BR112013012228B1 (pt) 2010-11-16 2023-02-28 University Of Southern California Método cosmético para tratar uma condição da pele e usos de um composto antagonista de cbp/catenina de molécula pequena
WO2012115286A1 (en) 2011-02-25 2012-08-30 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
US9353119B2 (en) 2011-08-09 2016-05-31 Jw Pharmaceutical Corporation Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
CN103930113B (zh) * 2011-08-09 2016-08-17 Jw制药公司 用于预防和治疗非小细胞肺癌的包含吡嗪并三嗪衍生物的组合物
KR20140094528A (ko) 2011-10-07 2014-07-30 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 cbp/카테닌 길항제
US10539191B2 (en) * 2011-11-16 2020-01-21 List Technology Ag Process for connecting functional elements to a shaft
CN104205744B (zh) * 2012-03-27 2017-03-01 索尼公司 信息处理设备、信息处理系统以及信息处理方法
CN105163760B (zh) 2012-12-12 2018-01-26 株式会社棱镜制药 肝纤维化的预防或治疗试剂
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
US10597398B2 (en) 2015-09-18 2020-03-24 National University Corporation Tottori University Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis
WO2017184808A1 (en) * 2016-04-20 2017-10-26 University Of Southern California Compounds and methods for increasing hematopoiesis
EP4051278A1 (en) 2019-10-29 2022-09-07 Eisai R&D Management Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
CN116925081A (zh) * 2022-04-11 2023-10-24 中国科学院上海药物研究所 一种环肽类化合物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3120859A1 (de) 1981-05-26 1982-12-23 Basf Ag, 6700 Ludwigshafen Dihalogenacetamide, verfahren zu ihrer herstellung und herbizide mittel, die acetanilide als herbizide wirkstoffe und diese dihalogenacetamide als antagonistische mittel enthalten
AU1570292A (en) * 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5475085A (en) * 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1994003494A1 (en) 1992-08-06 1994-02-17 The Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of reverse turns and peptides containing the same
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5693325A (en) * 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US6020331A (en) * 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6245764B1 (en) * 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) * 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5840833A (en) * 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
ATE320811T1 (de) 1996-08-05 2006-04-15 Myriad Genetics Inc Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6451972B1 (en) * 1998-11-16 2002-09-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
IT1308787B1 (it) 1999-07-05 2002-01-10 Fiat Ricerche Sistema di controllo della propulsione per un autoveicolo.
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US6872825B2 (en) * 1999-12-21 2005-03-29 The Procter & Gamble Company Peptide β-turn mimetic compounds and processes for making them
DE10005631A1 (de) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
GB2364210A (en) * 2000-06-30 2002-01-16 Nokia Oy Ab Diversity receiver and method of receiving a multi carrier signal
WO2002006279A1 (en) * 2000-07-17 2002-01-24 Oxigene Inc Efficient method of synthesizing combretastatin a-4 prodrugs
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
CA2453175A1 (en) 2001-07-09 2003-01-23 Pharmacia Italia Spa Interaction inhibitors of tcf-4 with beta-catenin
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
DE60227093D1 (de) 2001-10-12 2008-07-24 Choongwae Pharma Corp Reverse-turn-mimetika und diese betreffendes verfahren
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
US6955985B2 (en) * 2002-06-28 2005-10-18 Kopin Corporation Domain epitaxy for thin film growth
RS20050572A (en) 2003-02-13 2007-09-21 Sanofi-Aventis Deutschland Gmbh., Nitrogen-substituted hexahydropyrazino(1,2-a)pyrimidine – 4,7-dione derivatives, method for the production and use thereof as medicaments
KR20050111588A (ko) 2003-02-13 2005-11-25 사노피-아벤티스 도이칠란트 게엠베하 치환된 헥사하이드로피라지노[1,2-ａ]피리미딘-4,7-디온유도체, 이의 제조방법 및 약제로서의 이의 용도
AU2004268647B2 (en) * 2003-08-28 2010-07-01 Choongwae Pharma Corporation Modulation of beta-catenin/TCF activated transcription
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
US20070129353A1 (en) * 2005-11-08 2007-06-07 Michael Kahn Alpha-helix mimetics and method relating to the treatment of cancer stem cells
WO2007062243A2 (en) * 2005-11-28 2007-05-31 Choongwae Pharma Corporation Serum-free expansion of cells in culture
MX2010013277A (es) 2008-06-06 2011-04-27 Prism Biolab Corp Mimeticos de helice alfa y metodos relacionados con los mismos.

Also Published As

Publication number Publication date
KR101257824B1 (ko) 2013-04-29
KR20070008637A (ko) 2007-01-17
CA2562693A1 (en) 2005-12-08
EP1740588A2 (en) 2007-01-10
JP2007532674A (ja) 2007-11-15
US7576084B2 (en) 2009-08-18
AU2005247859B2 (en) 2011-06-16
US20070021425A1 (en) 2007-01-25
US20100081655A1 (en) 2010-04-01
US8101751B2 (en) 2012-01-24
WO2005116032A3 (en) 2006-04-13
CN1942472B (zh) 2012-02-15
CA2562693C (en) 2013-05-28
WO2005116032A2 (en) 2005-12-08
RU2006140383A (ru) 2008-05-27
RU2434017C2 (ru) 2011-11-20
BRPI0509888B1 (pt) 2021-10-13
US20110257185A1 (en) 2011-10-20
AU2005247859A1 (en) 2005-12-08
MXPA06011983A (es) 2007-08-14
CN1942472A (zh) 2007-04-04
US20150057283A1 (en) 2015-02-26
US8729262B2 (en) 2014-05-20
JP5021459B2 (ja) 2012-09-05
NZ550691A (en) 2010-10-29

Similar Documents

Publication Publication Date Title
BRPI0509888A (pt) miméticos de direção inversa e método relacionado aos mesmos
BRPI0409124A (pt) miméticos de direção inversa e método relacionado aos mesmos
ATE398129T1 (de) Reverse-turn-mimetika und diese betreffendes verfahren
DE69613861D1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
ATE301656T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
WO2009051397A3 (en) Novel compounds of reverse turn mimetics and the use thereof (3)
DE60043120D1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
BR9915604A (pt) Peptìdios inibidores de tgfbeta1
PT934325E (pt) Trisanidridos biciclicos de tetrafosfonato
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
DE69429095T2 (de) Humanisierte antikoerper
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
ATE251942T1 (de) Stapelbare statische mischelemente
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
WO2003014151A3 (en) Human secreted proteins, their encoding polynucleotides, and uses thereof
WO2002092010A3 (en) Reverse-turn mimetics and methods relating thereto
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
MA26252A1 (fr) Usine flottante de traitement d'hydrocarbures.
BR0318325A (pt) miméticos de beta-fita e método relacionado aos mesmos
PL374550A1 (en) Il-17 like molecules and uses thereof
BR112023024627A2 (pt) Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas
DE69922429D1 (de) Verwendung eines Adsorptionsmittels für die Trennung von halogenierten aromatischen Verbindungen und Trennungsverfahren unter Verwendung dieses Adsorptionsmittels
ATE305042T1 (de) Globale regulatoren von pathogenen bakteriellen genen; bakterielles selbstinduzierendes inaktivierungsprotein, die als ziele für die herstellung von krankheitsresistenzen einsetzbar sind
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2003011298A8 (en) Antibacterial oxazinones and methods for their use and synthesis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2718 DE 07-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.